Get the Stockscreener App
37.80
3.55%
-1.39
Lb Pharmaceuticals Inc stock is traded at $37.80, with a volume of 413.05K.
It is down -3.55% in the last 24 hours and down -21.59% over the past month.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
See More
Previous Close:
$39.19
Open:
$39.13
24h Volume:
413.05K
Relative Volume:
1.20
Market Cap:
$1.22B
Revenue:
-
Net Income/Loss:
$-38.95M
P/E Ratio:
-25.44
EPS:
-1.4857
Net Cash Flow:
$-50.43M
1W Performance:
-10.30%
1M Performance:
-21.59%
6M Performance:
+61.75%
1Y Performance:
+152.00%
1-Day Range:
$37.56
$39.39
1-Week Range:
$37.56
$43.40
52-Week Range:
$13.36
$50.16
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Name
Lb Pharmaceuticals Inc
Sector
Industry
Phone
917-450-6581
Address
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
37.80 | 1.22B | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | H.C. Wainwright | Buy |
| Apr-10-26 | Initiated | Craig Hallum | Buy |
| Jan-09-26 | Initiated | Roth Capital | Buy |
| Oct-06-25 | Initiated | Leerink Partners | Outperform |
| Oct-06-25 | Initiated | Piper Sandler | Overweight |
| Oct-06-25 | Initiated | Stifel | Buy |
View All
Lb Pharmaceuticals Inc Stock (LBRX) Latest News
LB Pharmaceuticals at TD Cowen summit: lb-102 aims for safer psychiatry - Investing.com Nigeria
LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity - Seeking Alpha
LB Pharmaceuticals Inc (LBRX) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
Form 8K LB Pharmaceuticals Inc For: 15 September By Investing.com - Investing.com Australia
LB Pharmaceuticals names Susan Kozauer as chief medical officer By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Names Dr. Susan Kozauer as Chief Medical Officer with Detailed Compensation Package - Kalkine Media
LB Pharmaceuticals names Susan Kozauer as chief medical officer - Investing.com
LB Pharmaceuticals Names Susan Kozauer Chief Medical Officer Ahead of Phase 3 Readout - citybiz
A doctor who helped develop an FDA-approved psychiatric drug joins LB Pharmaceuticals - Stock Titan
LB Pharmaceuticals (LBRX) CFO reports zero share ownership - Stock Titan
Bank of America Corp DE Has $410,000 Stock Position in LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals Inc (LBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bank of New York Mellon Corp Makes New $1.78 Million Investment in LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals (NASDAQ: LBRX) Names Joseph M. Miller as CFO with $530K Salary and 200,000-Share Stock Option - Kalkine Media
2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment - Yahoo Finance
LB Pharmaceuticals to Participate in Upcoming September Investor Events - GlobeNewswire
LB Pharmaceuticals Names Joseph M. Miller as CFO, Details Compensation and Severance Package - Kalkine Media
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 4.3%Here's What Happened - MarketBeat
LB Pharmaceuticals (NASDAQ: LBRX) Appoints Joseph M. Miller as CFO with $530K Salary and Equity Incentives - kalkinemedia.com
LB Pharmaceuticals Inc Announces Appointment of Joseph M. Miller to Chief Financial Officer, Effective September 2, 2026 - marketscreener.com
LB Pharmaceuticals Appoints Joseph Miller as New CFO - TipRanks
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer - The Manila Times
LB Pharmaceuticals Inc (LBRX) Q2 2026 Earnings: Wider-than-Expected Loss Sends Shares Down 3.96%Earnings Season Review - siam.in
LB Pharmaceuticals (LBRX) Edges Lower to $47.14 as Support HoldsCTA Positioning - dars.gov.et
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
HC Wainwright Issues Pessimistic Forecast for LBRX Earnings - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High After Analyst Upgrade - MarketBeat
H.C. Wainwright raises LB Pharmaceuticals price target to $60 By Investing.com - Investing.com India
H.C. Wainwright raises LB Pharmaceuticals price target to $60 - Investing.com
Great Lakes Advisors LLC Purchases Shares of 30,410 LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 12-Month HighTime to Buy? - MarketBeat
LB (LBRX) Technical Check: Climbs 1.88% to $47.10 on the Day; Level Position: the $44.74 to $49.46 Range Remains in FocusPositive Gamma - vinanet.vn
LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen - marketbeat.com
LB Pharmaceuticals (LBRX) investor group reports 5.0% beneficial stake in 13G/A - Stock Titan
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook By Investing.com - Investing.com South Africa
Stifel raises LB Pharmaceuticals stock price target on pipeline outlook - Investing.com
Stifel Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Raises Target Price to $53 - Moomoo
LB Pharmaceuticals (LBRX) Slips 2.45% as Key Support Levels Come into FocusOversold Bounce Ideas - dars.gov.et
LB PHARMACEUTICALS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $55 FROM $40 - webull.com
LB Pharmaceuticals Inc Common Stock (NASDAQ: LBRX) Stock Price, News & Analysis - Kalkine
BMO Capital Markets Increases LB Pharmaceuticals (NASDAQ:LBRX) Price Target to $54.00 - MarketBeat
LBRX SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Form 8K LB Pharmaceuticals Inc For: 11 August - Investing.com India
LB Pharmaceuticals Inc Stock 12‑Month Price Target Raised to $47.67, Implies 4% Upside - TradingView
LB Pharmaceuticals Submits Q2 2026 SEC Form 10-Q Reporting 32.26M Shares Outstanding - Kalkine Media
LB Pharmaceuticals2026 Funding Rounds & List of Investors - tracxn.com
LB Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Form 8K LB Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Q2 Loss Per Share Narrows - Yahoo Finance
LB PHARMACEUTICALS INC Q2 2026: Revenue $0 Net loss $(51.6M), EPS $(1.71) — 10-Q Summary - TradingView
Earnings Flash (LBRX) LB Pharmaceuticals Posts Q2 Loss $1.71 a Share, vs. FactSet Est of $0.81 Loss - marketscreener.com
Lb Pharmaceuticals Inc Stock (LBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):